Gout: New advances in the diagnosis and management of an old disease

International Journal of Clinical Rheumatology

Volumn 4, Issue 2, 2009, Pages 203-220

  Sivera, Francisca ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Gout; Monosodium urate crystals; Urate lowering therapy

Indexed keywords

ALLOPURINOL; BENZBROMARONE; BENZIODARONE; CLOFIBRATE; COLCHICINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOSTATIC AGENT; DIURETIC AGENT; ETHAMBUTOL; ETORICOXIB; FEBUXOSTAT; GLUCOCORTICOID; INDOMETACIN; LOOP DIURETIC AGENT; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROBENECID; PYRAZINAMIDE; RASBURICASE; SULFINPYRAZONE; THIAZIDE DIURETIC AGENT; URATE OXIDASE; URICOSURIC AGENT;

ABDOMINAL DISEASE; ABDOMINAL OBESITY; ATHEROSCLEROSIS; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIARRHEA; DIETARY INTAKE; DOSE KIDNEY FUNCTION RELATION; DRESS SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYNOVIAL FLUID; TREATMENT PLANNING; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; VOMITING;

EID: 70949106729     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.5     Document Type: Review

References (167)

1. Zhang W, Doherty M, Bardin T et al.: EULAR evidence based recommendations for gout - Part II management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 25, 1301-1311 (2006).
2. Zhang W, Doherty M, Pascual E et al.: EULAR evidence based recommendations for gout - Part I diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006).
3. Mikuls TR, MacLean CH, Olivieri J et al.: Quality of care indicators for gout management. Arthritis Rheum. 50, 937-943 (2004).
4. Pascual E, Sivera F: Why is gout so poorly managed? Ann. Rheum. Dis. 66(10), 1269-1270 (2007).
5. Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66(10), 1311-1315 (2007).
6. Perez-Ruiz F, Pascual E, Carmona L, De Miguel E, Ureña I, Gonzalez-Gay M: Diagnosis of gout in the rheumatology, hospital-based setting lies far from that recommended: results from the GEMA (gout evaluation of management) study. Ann. Rheum. Dis. 67(Suppl. 2), 246 (2008).
7. Singh J, Hodges J, Toscano J, Asch S: Quality of care for gout in the US needs improvement. Arthritis Rheum. 57(5), 822-829 (2007).
8. Mikuls T, Farrar J, Bilker W, Fernandes S, Saag K: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results form the UK General Practice Research Database (GPRD). Rheumatology 44, 1038-1042 (2005).
9. Mikuls T, Curtis J, Allison J, Hicks R, Saag K: Medication errors with the use of allopurinol and colchicine: a retrospective study of a national anonymous internet-accessible error reporting system. J. Rheumatol. 33, 562-566 (2006).
10. Perez-Ruiz F, Carmona L, De Miguel E, Ureña I, Pascual E, Gonzalez-Gay M: Variability in the treatment of gout: results from the GEMA audit of clinical practice. Ann. Rheum. Dis. 67(Suppl. 2), 246 (2008).
11. Annemans L, Spaepen E, Nash C, Bonnemaire M, Gilbert T, Malier V: Medical management of chronic gout in the UK and Germany. Ann. Rheum. Dis. 65(Suppl. 2), 430 (2006).
12. Sundy JS: Gout management: let's get it right this time. Arthritis Rheum. 59, 1535-1537 (2008).
13. Edwards NL: Treatment-failure gout: a moving target. Arthritis Rheum. 58(9), 2587-2590 (2008).
14. Terkeltaub R: Learning how and when to employ uricase as bridge therapy in refractory gout. J. Rheumatol. 34(10), 1955-1958 (2007).
15. McCarty DJ, Hollander JL: Identification of urate crystals in gouty synovial fluid. Ann. Intern. Med. 54, 452-460 (1961).
16. Terkeltaub RA: Clinical practice. Gout. N. Engl. J. Med. 349, 1647-1655 (2003).
17. Chen Lx, Schumacher HR: Current trends in crystal identification. Curr. Opin. Rheumatol. 18(2), 171-173 (2006).
18. Lumbreras B, Pascual E, Frasquet J et al.: Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann. Rheum. Dis. 64(4), 612-615 (2005).
19. Ivorra J, Rosas E, Pascual E: Most calcium pyrophosphate crystals appear as non-birefringent. Ann. Rheum. Dis. 58, 582-584 (1999).
20. Pascual E, Jovani V: Synovial fluid analysis. Best Pract. Res. Clin. Rheumatol. 19, 371-386 (2005).
21. Pascual E, Batlle-Gualda E, Martínez A et al.: Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med. 131(10), 756-759 (1999).
22. Pascual E, Sivera F: Time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout. Ann. Rheum. Dis. 66(8), 1056-1058 (2007).
23. Pascual E: Persistence of monosodium urate crystals, and low grade inflammation, in the synovial fluid of untreated gout. Arthritis Rheum. 34, 141-145 (1991).
24. Sivera F, Aragón R, Pascual E: First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann. Rheum. Dis. 67, 273-275 (2008).
25. Pascual E, Doherty M: Aspiration of normal or asymptomatic pathological joints for diagnosis and research - indications, technique and success rate. Ann. Rheum. Dis. 68(1), 3-7 (2009).
26. Simkin PA, Bassett JE, Lee QP: Not water, but formalin, dissolves urate crystals in tophaceous tissue samples. J. Rheumatol. 21, 2320-2321 (1994).
27. Velilla-Moliner J, Martinez-Burgui J, Cobeta-Garcia JC, Fatah-Bandpey ML: Podagra, is it always gout? Am. J. Emerg. Med. 22(4), 320-321 (2004).
28. Boulman N, Slobodin G, Sharif D, Rozenbaum M, Rosner I: Pseudopodagra: a manifestation of infective endocarditis. Clin. Exp. Rheumatol. 23(2), 251-253 (2005).
29. Beaudet F, de Medicis R, Magny P, Lussier A: Acute apatite podagra with negative birefringent spherulytes in the synovial fluid. J. Rheumatol. 20(11), 1975-1978 (1993).
30. Chen S, Chen C, Shen M, Kamatani N: Trends in the manifestations of gout in Taiwan. Rheumatology 42(12), 1529-1533 (2003).
31. Barthelemy I, Karanas Y, Sannajust JP et al.: Gout of the temporomandibular joint: pitfalls in diagnosis. J. Craniomacillofac. Surg. 29, 307-310 (2001).
32. De Santis D, Palazzi C, D'Amico E et al.: Acromioclavicular cyst and "porcupine shoulder" in gout. Rheumatology 40, 1320-1321 (2001).
33. Currey H: Letter: primary gout affecting the sternoclavicular joint. Br. Med. J. 1(6009), 583-584 (1976).
34. Perez-Ruiz F, Calabozo M, Alonso-Ruiz A: Gouty arthritis in the manubriosternal joint. Ann. Rheum. Dis. 56(9), 571 (1997).
35. Kerr R: Radiologic case study. Sacroiliac joint involvement by gout and hyperparathyroidism. Orthopedics 11, 187-190 (1988).
36. Justiniano ME, Colmegna I, Gimenez CR, Espinoza LR: Tophaceous gout of the symphysis pubis. Arthritis Rheum. 52(12), 4052 (2005).
37. Parhami N, Feng H: Gout in the hip joint. Arthritis Rheum. 36, 1029 (1993).
38. Nakajima A, Kato Y, Yamanaka H et al.: Spinal tophaceous gout mimcking a spinal tumor. J. Rheumatol. 31, 1459-1460 (2004).
39. Weinzweig J, Fletcher JW, Linburg RM: Flexor tendinitis and median nerve compression caused by gout in a patient with rheumatoid arthritis. Plast. Reconstr. Surg. 106, 1570-1572 (2000).
40. Hall A, Barry P, Dawber T, McNamara P: Epidemiology of gout and hyperuricemia: a long-term population study. Am. J. Med. 42, 27-37 (1967).
41. Campion E, Glynn R, DeLabry L: Asymptomatic hyperuricemia. Am. J. Med. 82, 421-426 (1987).
42. Wolfe F, Cathey MA: The misdiagnosis of gout and hyperuricemia. J. Rheumatol. 18, 1232-1234 (1991).
43. Urano W, Yamanaka H, Tsutani H et al.: ~The inflammatory process in the mechanisn of decreased serum uric acid concentration during acute gouty arthritis. J. Rheumatol. 29, 1950-1953 (2002).
44. Logan J, Morrison E, McGill P: Serum uric acid in acute gout. Ann. Rheum. Dis. 56, 696-697 (1997).
45. Schlesinger N, Baker D, Schumacher HR: Serum urate during bouts of acute gouty arthritis. J. Rheumatol. 24(11), 2265-2266 (1997).
46. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 20, 895-900 (1977).
47. Malik A, Schumacher H, Dinnella J, Clayburne G: Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J. Clin. Rheumatol. 15, 22-24 (2007).
48. Yu K, Luo S, Liou L et al.: Concomitant septic and gouty arthritis - an analysis of 30 cases. Rheumatology 42(9), 1062-1066 (2003).
49. Suk KS, Kim KT, Lee SH et al.: Tophaceous gout of the lumbar spine mimicking pyogenic discitis. Spine J. 7, 94-99 (2007).
50. Wazir NN, Moorthy V, Amalourde A, Lim HH: Tophaceous gout causing atlanto-axial subluxation mimicking rheumatoid arthritis: a case report. J. Orthop. Surg. (Hong Kong) 13(2), 203-206 (2005).
51. Li TJ, Lue KH, Lin ZI, Lu KH: Arthroscopic treatment for gouty tophi mimicking an intra-articular synovial tumor of the knee. Arthroscopy 22(8), 910, E1-E3 (2006).
52. Filippucci E, Riveros MG, Georgescu D, Salaffi F, Grassi W: Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Ostoarthr. Cartil. 17(2), 178-181 (2009).
53. Wright S, Filippucci E, McVeigh C et al.: High-resolution ultrasonography of the first metatarsophalangeal joint in gout: a controlled study. Ann. Rheum. Dis. 66(7), 859-864 (2007).
54. Thiele R, Schlesinger N: Diagnosis of gout by ultrasound. Rheumatology 46(7), 1116-1121 (2007).
55. Grassi W, Meenagh G, Pascual E, Filippucci E: "Crystal Clear"-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin. Arthritis Rheum. 36(3), 197-202 (2006).
56. Rettenbacher T, Ennemoser S, Weirich H et al.: Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur. Radiol. 18(3), 621-630 (2008).
57. Jordan KM, Cameron JS, Snaith M et al.: British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 46, 1372-1374 (2007).
58. Keith MP, Gilliland WR: Updates in the management of gout. Am. J. Med. 120, 221-224 (2007).
59. Pascual E, Sivera F: Therapeutic advances in gout. Curr. Opin. Rheumatol. 19, 122-127 (2007).
60. Schlesinger N: Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64(21), 2399-2416 (2004).
61. Yu T-F, Gutman AB. Mobilization of gouty tophi by protracted use of uricosuric agents. Am. J. Med. 11, 765-769 (1951).
62. Perez-Ruiz F, Liote F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 57, 1324-1328 (2007).
63. Li-Yu J, Clayburne G, Sieck M et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol. 28(3), 577-580 (2001).
64. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356-360 (2002).
65. Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd: Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum. 58(11), 3632-3634 (2008).
66. Puig JG, de Miguel E, Castillo MC, Rocha AL, Martínez MA, Torres RJ: Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 27(6), 592-595 (2008).
67. Vukmir RB, Weiss L, Verdile VP: Polyarticular symmetric tophaceous joint inflammation as the initial presentation of gout. Am. J. Emerg. Med. 8(1), 43-45 (1990).
68. Meyers OL, Monteagudo FSE: Gout in females: an analysis of 92 patients. Clin. Exp. Rheumatol. 3, 105-109 (1985).
69. Dalbeth N, Clark B, Gregory K et al.: Mechanisms of bone erosion in gout; a quantitative analysis using plain radiography and computed tomography. Ann. Rheum. Dis. (2008) (Epub ahead of print).
70. Pascual E, Jovani V: A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Br. J. Rheumatol. 34, 724-726 (1995).
71. Pascual E, Castellano JA: Treatment with colchicine decreases the white cell counts in the synovial fluid of asymptomatic knees which contain monosodium urate crystals. J. Rheumatol. 19, 600-603 (1992).
72. Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum. 54, 2688-2696 (2006).
73. Choy HK, Curhan G: Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116, 894-900 (2007).
74. Chen SY, Chen CL, Shen ML: Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin. Rheumatol. 26, 308-313 (2007).
75. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003).
76. Roman MJ, Shanker BA, Davis A et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
77. Alderman MH: Podagra, uric acid, and cardiovascular disease. Circulation 116, 880-883 (2007).
78. van Lieshout-Zuidema MF, Breedveld FC: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J. Rheumatol. 20, 1383-1385 (1993).
79. Bull PW, Scott JT: Intermittent control of hyperuricemia in the treatment of gout. J. Rheumatol. 16, 1246-1248 (1989).
80. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM: Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 55, 786-790 (2006).
81. Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T: Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J. Rheumatol. 34, 2093-2098 (2007).
82. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM: Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin. Pharmacokinet. 46, 623-644 (2007).
83. Product information: Zyloprim, allopurinol. Faro Pharmaceuticals, Bedminster, NJ, USA (PI revised reviewed 2/2000, 2/99).
84. Becker MA, Schumacher HR Jr, Wortmann RL et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, Phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916-923 (2005).
85. Becker MA, Schumacher HR, Wortmann RL et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Eng. J. Med. 353, 2450-2461 (2005).
86. Schumacher HR Jr, Becker MA, Wortmann RL et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540-1548 (2008).
87. Perez-Ruiz F, Alonso Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann. Rheum. Dis. 57, 545-549 (1998).
88. Reinders MK, Haagsma C, Jansen TL et al.: A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann. Rheum. Dis. (2008) (Epub ahead of print).
89. Reinders MK, van Roon EN, Jansen TL et al.: Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 68(1), 51-56 (2009).
90. Sarawate CA, Brewer KK, Yang W et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin. Proc. 81, 925-934 (2006).
91. Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG: Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous internet-accessible error reporting system. J. Rheumatol. 33, 562-566 (2006).
92. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M: Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J. Rheumatol. 31, 1575-1581 (2004).
93. Annemans L, Spaepen E, Nash C et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann. Rheum. Dis. 67, 960-966 (2008).
94. Emmerson BT, Gordon RB, Thomson DB: Plasma oxipurinol concentrations during allopurinol therapy. Br. J. Rheumatol. 26, 445-449 (1987).
95. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity:description and guidelines for prevention in patients with renal insufficiency. Am. J. Med. 76, 47-56 (1984).
96. Perez-Ruiz F, Hernando I, Villar I, Nolla JM: Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J. Clin. Rheumatol. 11, 129-133 (2005).
97. Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J. Rheumatol. 33, 1646-1650 (2006).
98. Dalbeth N, Stamp L: Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin. Dial. 20, 391-395 (2007).
99. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann. Rheum. Dis. 60, 981-983 (2001).
100. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47, 51-59 (2006).
101. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI: Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 86, 287-291 (2000).
102. Gibson T, Rodgers V, Potter C, Simmonds HA: Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann. Rheum. Dis. 41, 59-65 (1982).
103. Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924-932 (2008).
104. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-De la Villa F: Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 331, 623-624 (2005).
105. Shalom R, Rimbroth S, Rozenman D, Markel A: Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren. Fail. 30, 327-329 (2008).
106. Halevy S, Ghislain PD, Mockenhaupt M et al.; EuroSCAR Study Group: Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58, 25-32 (2008).
107. Fam AG, Lewtas J, Stein J, Paton TW: Desensitization to allopurinol in patients with gout and cutaneous reactions. Am. J. Med. 93, 299-302 (1992).
108. Perez-Ruiz F, Calabozo M, García-Erauskin G, Ruibal A, Herrero Beites AM: Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 47, 610-613 (2002).
109. Jansen TL, Reinders MK, van Roon EN, Brouwers JR: Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? Clin. Exp. Rheumatol. 22, 651 (2004).
110. Lee MH, Graham GG, Williams KM, Ray RO: A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 31, 643-665 (2008).
111. Kumar S, Ng J, Gow P: Benzbromarone therapy in the management of refractory gout. N. Z. Med. J. 118(1217), U1533 (2005).
112. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ et al.: Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. J. Clin. Rheumatol. 5, 49-55 (1999).
113. Zürcher RM, Bock HA, Thiel G: Excellent uricosuric efficacy of benzbromarone in cyclosporin-A treated renal transplant patients: a prospective study. Nephrol. Dial. Trasplant. 9, 549-551 (1994).
114. Marcen R, Gallego N, Orofino L et al.: Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 70, 307-313 (1995).
115. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ et al.: Long-term efficacy of hyperuricaemia treatment in renal transplant patients Nephrol. Dial. Transplant. 18(3), 603-606 (2003).
116. Becker MA, Kisicki J, Khosravan R et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 23, 1111-1116 (2004).
117. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ: Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am. J. Ther. 12, 22-34 (2005).
118. Watanabe S, Kang DH, Feng L et al.: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40(3), 355-360 (2002).
119. Oda M, Satta Y, Takenaka O, Tanaka N: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol. Biol. Evol. 19, 240-253 (2002).
120. Goldman SC, Holcemberg JS, Finkensltein JZ et al.: A randomized comaprison between rasburicase and allopurinol with lymphoma or leukemia at high risk for tumor lysis. Blood 97, 2998-3003 (2001).
121. Vogt B: Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol. Dial. Transplant. 20, 431-433 (2005).
122. Richette P, Bardin T: Successful treatment with rasburicase of tophaceous gout in a patient allergic to allopurinol. Nat. Clin. Pract. Rheumatol. 2, 338-342 (2006).
123. Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin. Rheumatol. 25, 749-752 (2006).
124. Cammalleri L, Malaguarnera M: Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int. J. Med. Sci. 4, 83-93 (2007).
125. Sundy JS, Becker MA, Baraf HS et al.: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a Phase II randomized study. Arthritis Rheum. 58, 2882-2891 (2008).
126. Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review. Rheumatology 45, 1422-1431 (2006).
127. Rubin BR, Burton R, Navarra S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 50, 598-606 (2004).
128. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371(9627), 1854-1860 (2008).
129. Groff GD, Franck WA, Raddatz DA: Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin. Arthritis Rheum. 19, 329-336 (1990).
130. Janssens HJEM, Lucassen PLBJ, Van de Laar FA, Janssen M, Van de Lisdonk EH: Systemic corticosteroids for acute gout. Review Cochrane Syst. Rev. 16(2), CD005521 (2008).
131. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H: ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J. Rheumatol. 21, 696-699 (1994).
132. Fernandez C, Gonzalez JA, Noguera R, Pascual E: Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J. Rheumatol. 26(10), 2285-2286 (1999).
133. Pascual E, Trenor P, Medrano C: Management of gout in patients with renal insufficiency and a gastrointestinal bleed - an answer to Dr Dunne's letter. Br. J. Rheumatol. 34, 481-482 (1995).
134. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks MP, Jones M: Does colchicine work? The results of the first controlled study in acute gout. Aust. N. Z. J. Med. 17, 301-304 (1987).
135. Terkeltaub R, Furst DE, Bennett K, Kook K, Davis M: Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum. 58(Abstract) (2008) (In press).
136. Terkeltaub RA: Colchicine update: 2008. Semin. Arthritis Rheum. (2008) (Epub ahead of print).
137. Altman A, Szyper-Kravitz M, Shoenfeld Y: Colchicine-induced rhabdomyolysis. Clin. Rheumatol. 26, 2197-2199 (2007).
138. Tausche AK, Richter K, Grassler A, Hansel S, Roch B, Schroeder HE: Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor a as a new therapeutic option. Ann. Rheum. Dis. 64, 516 (2005).
139. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
140. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R: Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients Arthritis Rheum. 17(5), 609-614 (1974).
141. Yu T: The efficacy of colchicine prophylaxis in articular gout. A reappraisal after 20 years. Semin. Arthritis Rheum. 12, 256-264 (1992).
142. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Invest. 96(2), 994-1002 (1995).
143. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31, 2429-2432 (2004).
144. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr: Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin. Exp. Rheumatol. 19, 595 (2001).
145. Sarawate CA, Patel PA, Schumacher HR Jr, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: ana lysis from managed care data. J. Clin. Rheumatol. 12, 61-65 (2006).
146. Ordi J, Alonso PL, de Zulueta J et al.: The severe gout of Holy Roman Emperor Charles V. N. Engl. J. Med. 355(5), 516-520 (2006).
147. Roddy E, Zhang W, Doherty M: The changing epidemiology of gout. Nat. Clin. Pract. Rheumatol. 3(8), 443-449 (2007).
148. Miao Z, Li C, Chen Y et al.: Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 35(9), 1859-1864 (2008).
149. Choi HK, Ford ES, Li C, Curhan G: Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 57(1), 109-115 (2007).
150. Choi HK, Ford ES: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 120(5), 442-447 (2007).
151. Facchini F, Chen Y-D, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266, 3008-3011 (1991).
152. Tinahones FJ, Perez Lindon G, C-Soriguer FJ, Pareja A, Sanchez Guijo P, Collantes E: Dietary alterations in plasma very low density lypoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J. Clin. Endocrinol. Metab. 82, 1188-1191 (1997).
153. Lee SJ, Terkeltaub RA, Kavanaugh A: Recent developments in diet and gout. Curr. Opin. Rheumatol. 18, 193-198 (2006).
154. Choi HK, Curhan G: Gout: epidemiology and lifestyle choices. Curr. Opin. Rheumatol. 17, 341-345 (2005).
155. Fam AG: Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet. J. Rheumatol. 32, 773-777 (2005).
156. Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res. Ther. 8 (Suppl. 1), S2 (2006).
157. Choi JW, Ford ES, Gao X, Choi HK: Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 59, 109-116 (2008).
158. Choi HK, Curhan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336, 309-312 (2008).
159. Choi HK, Willett W, Curhan G: Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 56(6), 2049-2055 (2007).
160. Choi HK, Curhan G: Cofee, tea and caffeine consumption andserum uric acid level: the third national helath and nutrition examination survey. Arthritis Rheum. 57(5), 816-821 (2007).
161. Choi HK, Liu S, Curhan G: Intake of purine-rich foods, protein and dairy products and relationship to serum levels of uric acid; the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 52(1), 283-289 (2005).
162. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y: Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J. Rheumatol. 33, 1341-1345 (2006).
163. Janssens HJ, van de Lisdonk EH, Jannsen M, van den Hoogen HJ, Verbeek AL: Gout, not induced by diuretics? A case-control study from primary care. Ann. Rheum. Dis. 65(8), 1080-1083 (2006).
164. Pascual E, Perdiguero M: Gout, diuretics and the kidney. Ann. Rheum. Dis. 65, 981-982 (2006).
165. Scott JT: Drug-induced gout. Baillieres Clin. Rheumatol. 5, 39-60 (1991).
166. American College of Rheumatology: Core curriculum outline for rheumatology fellowship programs: a competency-based guide to curriculum development (2006). www.rheumatology.org/educ/training/cco.doc.
167. UEMS Section of Rheumatology: core curriculum for specialist training. www.uems-rheumatology.net/.